Sign In — Diabetes Care

This item requires a subscription to Diabetes Care.

Original Research:

Steven E. Kahn,
Steven M. Haffner,
Giancarlo Viberti,
William H. Herman,
John M. Lachin,
Barbara G. Kravitz,
Dahong Yu,
Gitanjali Paul,
Rury R. Holman,
Bernard Zinman,
and for the ADOPT Study Group

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial) Diabetes Care ; published ahead of print October 6, 2009, doi:10.2337/dc09-1661

Pay for Admission - You may access all content in Diabetes Care (from the computer you are currently using) for 30 days for US$45.00.
Regain Access - You can regain access to a recent Pay for Admission purchase if your access period has not yet expired.